HC Wainwright initiates Buy on Vanda Pharmaceuticals with an $18 price target, citing undervaluation, a strong product ...

WASHINGTON, Nov. 12, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the following upcoming investor conferences in November ...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating, citing its negative enterprise ...

Vanda Pharmaceuticals ( (VNDA) ) has released its Q3 earnings. Here is a breakdown of the information Vanda Pharmaceuticals presented to its ...

Update 11:15am: Adds Vanda response, updates shares. Vanda Pharmaceuticals (NASDAQ:VNDA) jumped 11% after Cycle Pharmaceuticals reaffirmed its $8/share all cash offer for the company. "Cycle is ...

The FDA’s rejection of Vanda Pharmaceuticals’ stomach disease candidate has done little to dampen the enthusiasm of England’s Cycle Pharmaceuticals to acquire the Washington D.C.-based company.

Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating on Vanda (VNDA – Research Report) today and set a price target of $13.00. The company’s shares closed yesterday at $4.89. Duncan covers ...

WASHINGTON (AP) — WASHINGTON (AP) — Vanda Pharmaceuticals Inc. (VNDA) on Wednesday reported a loss of $5.3 million in its third quarter. The Washington-based company said it had a loss of 9 ...

Oct 14 (Reuters) - Vanda Pharmaceuticals (VNDA.O), opens new tab on Monday rejected UK-based Cycle Pharmaceuticals' second takeover proposal, which values the drugmaker at $8 per share despite a ...

英为财情Investing.com - Vanda Pharmaceuticals (NASDAQ: VNDA )星期三发布了第三季度的财报，数据显示，公司营收逊于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$-0.09，总营收为$47.7M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$50.75M，每股收益为$-0 ...

H.C. Wainwright initiated coverage of Vanda Pharmaceuticals (NASDAQ:VNDA) with a buy rating, citing its negative enterprise value. The investment bank said its rating was based on Vanda’s well ...